Document:

<PAGE>

                                                                   EXHIBIT 10.12

                             TAX SHARING AGREEMENT

                                    BETWEEN

                                SERACARE, INC.

                                      AND

                         SERACARE LIFE SCIENCES, INC.

                                 JUNE 10, 2001

                                      -1-
<PAGE>

                               TABLE OF CONTENTS

<TABLE>
<CAPTION>
                                                                                                            Page
<S>                                                                                                         <C>
                                                     ARTICLE I

                                                    DEFINITIONS

Section 1.1    Action.....................................................................................     1
Section 1.2    Ancillary Agreements.......................................................................     1
Section 1.3    Code.......................................................................................     1
Section 1.4    Disputes...................................................................................     1
Section 1.5    Distribution...............................................................................     1
Section 1.6    Distribution Date..........................................................................     1
Section 1.7    Final Determination........................................................................     1
Section 1.8    Income Tax.................................................................................     2
Section 1.9    Income Tax Liability.......................................................................     2
Section 1.10   Income Tax Return..........................................................................     2
Section 1.11   Indemnified Party..........................................................................     2
Section 1.12   Indemnifying Party.........................................................................     2
Section 1.13   IRS........................................................................................     2
Section 1.14   Merger.....................................................................................     2
Section 1.15   Merger Agreement...........................................................................     2
Section 1.16   Person.....................................................................................     2
Section 1.17   Post-Distribution Tax Attribute............................................................     3
Section 1.18   Post-Distribution Taxable Period...........................................................     3
Section 1.19   Pre-Distribution Tax Attribute.............................................................     3
Section 1.20   Pre-Distribution Taxable Period............................................................     3
Section 1.21   Proceeding.................................................................................     3
Section 1.22   Refund.....................................................................................     3
Section 1.23   Separation Agreement.......................................................................     3
Section 1.24   SeraCare Consolidated Federal Return.......................................................     3
Section 1.25   SeraCare Consolidated Group................................................................     3
Section 1.26   SeraCare Consolidated Returns..............................................................     3
Section 1.27   SeraCare Consolidated Return Period........................................................     3
Section 1.28   SeraCare Consolidated Tax Liability........................................................     4
Section 1.29   SeraCare State and Local Returns...........................................................     4
Section 1.30   Subsidiary.................................................................................     4
Section 1.31   Tax Attribute..............................................................................     4
Section 1.32   Taxing Jurisdiction........................................................................     4
Section 1.33   Life Sciences..............................................................................     4
</TABLE>

                                      -i-
<PAGE>

                               TABLE OF CONTENTS
                                  (continued)

<TABLE>
<CAPTION>
                                                                                                         Page
<S>                                                                                                      <C>
                                                 ARTICLE II

                            PREPARATION AND FILING OF TAX RETURNS; PAYMENT OF TAX

Section 2.1    Federal Returns of SeraCare............................................................      4
Section 2.2    State and Local Returns of SeraCare....................................................      5
Section 2.3    Income Tax Liability...................................................................      6
Section 2.4    Life Sciences Separate Returns and Income Tax Liability................................      6

                                                 ARTICLE III

                                      INDEMNIFICATION FOR INCOME TAXES

Section 3.1    Indemnification by SeraCare............................................................      6
Section 3.2    Indemnification by Life Sciences.......................................................      6

                                                 ARTICLE IV

                                             INCOME TAX CONTESTS

Section 4.1    Notification...........................................................................      7
Section 4.2    Proceedings Involving SeraCare.........................................................      7
Section 4.3    Power of Attorney......................................................................      7

                                                  ARTICLE V

                     APPORTIONMENT OF TAX ATTRIBUTES; REFUNDS; TAX SHARING AGREEMENTS

Section 5.1    Apportionment of Tax Attributes........................................................      8
Section 5.2    Refunds................................................................................      8
Section 5.3    Carrybacks.............................................................................      8
Section 5.4    Retention of Carryovers................................................................      8
Section 5.5    Tax Sharing Agreements.................................................................      8

                                                 ARTICLE VI

                                   COOPERATION AND EXCHANGE OF INFORMATION

Section 6.1    Cooperation............................................................................      8
Section 6.2    Retention of Records...................................................................      9
</TABLE>

                                     -ii-
<PAGE>

                               TABLE OF CONTENTS
                                  (continued)

<TABLE>
<CAPTION>
                                                                                                         Page
<S>                                                                                                      <C>
                                                    ARTICLE VII

                                                     PAYMENTS

Section 7.1    Method of Payment......................................................................      9
Section 7.2    Interest...............................................................................      9
Section 7.3    Characterization of Payments...........................................................     10
Section 7.4    Time of Indemnification Payment........................................................     10

                                                ARTICLE VIII

                                          MISCELLANEOUS PROVISIONS

Section 8.1    Entire Agreement.......................................................................     10
Section 8.2    Dispute Resolution.....................................................................     10
Section 8.3    Governing Law..........................................................................     10
Section 8.4    Notices................................................................................     10
Section 8.5    Agent..................................................................................     10
Section 8.6    Amendment..............................................................................     11
Section 8.7    Counterparts...........................................................................     11
Section 8.8    Binding Effect; Assignment.............................................................     11
Section 8.9    Severability...........................................................................     11
Section 8.10   Waiver of Breach.......................................................................     11
Section 8.11   Amendment and Execution................................................................     11
Section 8.12   Authority..............................................................................     11
Section 8.13   Descriptive Headings...................................................................     11
Section 8.14   Gender and Number......................................................................     12
Section 8.15   Additional Assurances..................................................................     12
Section 8.16   Force Majeure..........................................................................     12
</TABLE>

                                     -iii-
<PAGE>

                             TAX SHARING AGREEMENT

         This Tax Sharing Agreement (this "Agreement") is entered into as of
June 10, 2001, by and between SeraCare, Inc., a Delaware corporation
("SeraCare"), and SeraCare Life Sciences, Inc., a California corporation and
wholly-owned subsidiary of SeraCare ("Life Sciences"). SeraCare and Life
Sciences are sometimes referred to herein individually as a "party" or
collectively as the "parties."

                                   RECITALS

         WHEREAS, pursuant to an Agreement and Plan of Merger dated June 10,
2001 (the "Merger Agreement") by and between SeraCare, Instituto Grifols, S.A.,
a company organized under the laws of Spain ("Grifols"), and SI Merger Corp., a
Delaware corporation and wholly-owned subsidiary of Grifols, Grifols will
acquire all of the outstanding stock of SeraCare by merging SI Merger Corp. with
and into SeraCare (the "Merger");

         WHEREAS, as a condition of, and immediately prior to, the Merger,
SeraCare will declare a pro rata distribution to its stockholders of all of the
capital stock of Life Sciences (the "Distribution");

         WHEREAS, at the close of the business on the date the Distribution is
effective, Life Sciences will cease to be a member of the SeraCare Consolidated
Group (as defined below); and

         WHEREAS, as a result of the Distribution the parties hereto wish to
provide for the payment of Income Taxes (as defined herein) and entitlement to
refunds thereof, allocate responsibility and provide for cooperation in
connection with the filing of returns in respect of Income Taxes, and provide
for certain other matters relating to Income Taxes.

         NOW, THEREFORE, in consideration of the agreements herein contained and
intending to be legally bound hereby, SeraCare and Life Sciences hereby agree as
follows:

                                   ARTICLE I
                                  DEFINITIONS

         For the purpose of this Agreement the following capitalized terms are
defined in this Article I.

         Section 1.1  Action. "Action" means any action, claim, suit,
                      ------
arbitration, inquiry, proceeding or investigation by or before any court, any
governmental, regulatory or other administrative agency or commission or any
arbitration tribunal.

         Section 1.2  Ancillary Agreements. "Ancillary Agreements" has the
                      --------------------
meaning set forth in Section 2.1 of the Separation Agreement.

         Section 1.3  Code.  "Code" means the Internal Revenue Code of 1986, as
                      ----
amended.

                                      -1-
<PAGE>

         Section 1.4  Disputes.  "Disputes" has the meaning set forth in Section
                      --------
7.6 of the Separation Agreement.

         Section 1.5  Distribution.  "Distribution" has the meaning set forth in
                      ------------
the Recitals hereof.

         Section 1.6  Distribution Date. "Distribution Date" has the meaning set
                      -----------------
forth in Section 3.2(a) of the Separation Agreement.

         Section 1.7  Final Determination. "Final Determination" means the final
                      -------------------
resolution of liability for any Income Tax, which resolution may be for a
specific issue or adjustment or for a taxable period: (i) by Internal Revenue
Service Form 870 or 870-AD (or any successor forms thereto), on the date of
acceptance by or on behalf of the taxpayer, or by a comparable form under the
laws of a state or local Taxing Jurisdiction, except that a Form 870 or 870-AD
or comparable form shall not constitute a Final Determination to the extent that
it reserves (whether by its terms or by operation of law) the right of the
taxpayer to file a claim for Refund or the right of the Taxing Jurisdiction to
assert a further deficiency in respect of such issue or adjustment or for such
taxable period (as the case may be); (ii) by a decision, judgment, decree, or
other order by a court of competent jurisdiction, which has become final and
unappealable; (iii) by a closing agreement or accepted offer in compromise under
Sections 7121 or 7122 of the Code, or a comparable agreement under the laws of a
state or local taxing jurisdiction; (iv) by any allowance of a Refund or credit
in respect of an overpayment of Income Tax, but only after the expiration of all
periods during which such Refund may be recovered (including by way of offset)
by the jurisdiction imposing such Income Tax; or (v) by any other final
disposition, including by reason of the expiration of the applicable statute of
limitations or by mutual agreement of the parties.

         Section 1.8  Income Tax. "Income Tax" (a) means (i) any foreign or any
                      ----------
United States federal, state or local tax, charge, fee, impost, levy or other
assessment that is based upon, measured by, or calculated with respect to (1)
net income or profits (including, but not limited to, any capital gains, gross
receipts, or minimum tax, and any tax on items of tax preference, but not
including sales, use, value added, real property gains, real or personal
property, transfer or similar taxes), or (2) multiple bases (including, but not
limited to, corporate franchise, doing business or occupation taxes), if one or
more of the bases upon which such tax may be based, by which it may be measured,
or with respect to which it may be calculated is described in clause (a)(i)(1)
of this definition, in either case, together with any interest and any
penalties, fines, additions to tax or additional amounts imposed by any Taxing
Jurisdiction with respect thereto and (b) shall include any liability in respect
of an amount described in clause (a) of this definition resulting from the
application of Treasury Regulations ss.1.1502-6 or similar provision under state
or local law, or as a transferee.

         Section 1.9  Income Tax Liability.  "Income Tax Liability" means all
                      --------------------
liabilities for Income Taxes.

         Section 1.10 Income Tax Return. "Income Tax Return" means any return,
                      -----------------
report, filing, statement, questionnaire, declaration or other document that has
been or is required to be filed with a Taxing Jurisdiction in respect of Income
Taxes.

                                      -2-
<PAGE>

          Section 1.11  Indemnified Party. "Indemnified Party" means any Person
                        -----------------
seeking indemnification pursuant to the provisions of this Agreement.

          Section 1.12  Indemnifying Party. "Indemnifying Party" means any party
                        ------------------
hereto from which any Indemnified Party is seeking indemnification pursuant to
the provisions of this Agreement.

          Section 1.13  IRS.  "IRS" means the Internal Revenue Service.
                        ---

          Section 1.14  Merger. "Merger" has the meaning given that term in the
                        ------
Recitals hereof.

          Section 1.15  Merger Agreement. "Merger Agreement" has the meaning
                        ----------------
given that term in the Recitals hereof.

          Section 1.16  Person. "Person" means any individual, partnership,
                        ------
joint venture, limited liability company, corporation, association, joint stock
company, trust, unincorporated organization or similar entity or a governmental
authority or any department or agency or other unit thereof.

          Section 1.17  Post-Distribution Tax Attribute. "Post-Distribution Tax
                        -------------------------------
Attribute" means a Tax Attribute that arises in a Post-Distribution Taxable
Period and can be carried back to a Pre-Distribution Taxable Period.

          Section 1.18  Post-Distribution Taxable Period. "Post-Distribution
                        --------------------------------
Taxable Period" means a taxable period that, to the extent it relates to Life
Sciences and its Subsidiaries, begins after midnight on the Distribution Date.

          Section 1.19  Pre-Distribution Tax Attribute. "Pre-Distribution Tax
                        ------------------------------
Attribute" means a Tax Attribute that arises in a Pre-Distribution Taxable
Period (including the taxable period in which the Distribution Date occurs) and
can be carried to a Post-Distribution Taxable Period.

          Section 1.20  Pre-Distribution Taxable Period. "Pre-Distribution
                        -------------------------------
Taxable Period" means a taxable period that, to the extent it relates to Life
Sciences and its Subsidiaries, ends on or before midnight on the Distribution
Date.

          Section 1.21  Proceeding. "Proceeding" means any audit or other
                        ----------
examination, judicial or administrative proceeding relating to liability for, or
Refunds or adjustments with respect to, Income Taxes.

          Section 1.22  Refund. "Refund" means any refund of Income Taxes,
                        ------
including any reduction in Income Tax Liabilities by means of a credit, offset
or otherwise.

          Section 1.23  Separation Agreement. "Separation Agreement" means the
                        --------------------
Master Separation and Distribution Agreement dated as of the date hereof between
the parties, to which this Agreement is attached as Exhibit F.

                                      -3-
<PAGE>

          Section 1.24  SeraCare Consolidated Federal Return. "SeraCare
                        ------------------------------------
Consolidated Federal Return" means any consolidated federal Income Tax Return or
amendment thereof of the SeraCare Consolidated Group for any SeraCare
Consolidated Return Period.

          Section 1.25  SeraCare Consolidated Group. "SeraCare Consolidated
                        ---------------------------
Group" means SeraCare and, with respect to federal Income Taxes, the other
members of the affiliated group of corporations (within the meaning of Section
1504(a) of the Code) of which SeraCare was the common parent prior to the
Merger, and with respect to state or local Income Taxes, any other corporations
with whom SeraCare filed or files a consolidated, combined or unitary Income Tax
Return with SeraCare as the common parent. Notwithstanding the foregoing, Life
Sciences shall cease to be a member of the SeraCare Consolidated Group after
midnight on the Distribution Date, and shall not be a member of the SeraCare
Consolidated Group for any Post-Distribution Taxable Period.

          Section 1.26  SeraCare Consolidated Returns. "SeraCare Consolidated
                        -----------------------------
Returns" means all SeraCare Consolidated Federal Returns and all SeraCare State
and Local Returns.

          Section 1.27  SeraCare Consolidated Return Period. "SeraCare
                        -----------------------------------
Consolidated Return Period" means a taxable period that ends on, before, or
includes the Distribution Date for which a consolidated, combined or unitary (as
applicable) federal, state or local Income Tax Return is filed or required to be
filed by the SeraCare Consolidated Group or by a member thereof (except any
Income Tax Return filed or required to be filed by Life Sciences with respect to
any Post-Distribution Taxable Period).

          Section 1.28  SeraCare Consolidated Tax Liability. "SeraCare
                        -----------------------------------
Consolidated Tax Liability" means the consolidated, combined or unitary Income
Tax Liability of the SeraCare Consolidated Group.

          Section 1.29  SeraCare State and Local Returns. "SeraCare State and
                        --------------------------------
Local Returns" means any combined, consolidated or unitary state or local Income
Tax Returns or amendments thereof that are required to be filed by SeraCare or a
member of the SeraCare Consolidated Group for any SeraCare Consolidated Return
Period.

          Section 1.30  Subsidiary. "Subsidiary" has the meaning set forth in
                        ----------
Section 9.35 of the Separation Agreement.

          Section 1.31  Tax Attribute. "Tax Attribute" means a consolidated net
                        -------------
operating loss, a consolidated net capital loss, a consolidated unused
investment credit, a consolidated unused foreign tax credit, or a consolidated
excess charitable contribution (as such terms are used in Treasury Regulations
ss.ss.1.1502-79 and 1.1502-79A) or analogous provisions of state or local law,
or a U.S. federal minimum tax credit or U.S. federal general business credit or
analogous provisions of state or local law (but not tax basis or earnings and
profits).

          Section 1.32  Taxing Jurisdiction. "Taxing Jurisdiction" means the
                        -------------------
United States and every other government or governmental unit, whether domestic
or foreign, having jurisdiction to tax SeraCare, Life Sciences or any of their
respective affiliates.

                                      -4-
<PAGE>

          Section 1.33  Life Sciences. "Life Sciences" has the meaning set forth
                        -------------
in the preamble and shall include for all purposes of this Agreement its
Subsidiaries.

                                  ARTICLE II
             PREPARATION AND FILING OF TAX RETURNS; PAYMENT OF TAX

          Section 2.1  Federal Returns of SeraCare.
                       ---------------------------

                (a) General. Except as provided herein, SeraCare shall have sole
                    -------
and exclusive responsibility for the preparation and filing of all SeraCare
Consolidated Federal Returns, and any amendments thereto, with the IRS. SeraCare
shall, on a timely basis, file or cause to be filed all SeraCare Consolidated
Federal Returns and estimated tax returns of the SeraCare Consolidated Group as
are required to be filed in its sole discretion. SeraCare shall have the right
to: determine the manner in which all such returns shall be filed; make any
elections in connection with any such returns; contest, compromise and settle
any adjustments of deficiency proposed, asserted or assessed in connection with
any such returns; file, pursue, compromise or settle any claim for refund; and
determine whether any refunds to which the SeraCare Consolidated Group is
entitled shall be paid by way of a refund or credit. Notwithstanding the
foregoing, such returns shall be filed in a manner consistent with an allocation
of items of income, gain, loss or deduction of SeraCare and all other members of
the SeraCare Consolidated Group, including Life Sciences (including any deferred
income triggered into income by Treasury Regulations ss. 1.1502-13 and ss.
1.1502-14 and any excess loss accounts taken into income under Regulations ss.
1.1502-19) based upon Treasury Regulations ss.1.1502-76(b)(1)(ii) on an accrual
basis, and using a "closing of the books" method.

                (b) Notwithstanding Section 2.1(c) and (d), SeraCare shall have
the sole authority to take any position on SeraCare Consolidated Federal Returns
(including any amended returns) to the extent that such position is consistent
with SeraCare's prior practice. To the extent such position on SeraCare
Consolidated Federal Returns is related to the Income Tax Liability of Life
Sciences, Life Sciences and SeraCare shall cooperate with each other reasonably
and in good faith to determine whether any such position is consistent with
SeraCare's prior practice, is inconsistent with SeraCare's prior practice, or
has no comparable prior practice.

                (c) SeraCare shall allow Life Sciences an opportunity to review
and comment upon such SeraCare Consolidated Federal Returns (including any
amended returns) to the extent that they relate to the Income Tax Liability of
Life Sciences solely to the extent that positions taken on such returns are
inconsistent with SeraCare's prior practice or have no comparable prior
practice. For any position on such SeraCare Consolidated Federal Returns that is
inconsistent with SeraCare's prior practice or has no comparable prior practice,
and that relates to the Income Tax Liability of Life Sciences that would affect
Life Sciences on or after the date hereof, Life Sciences and SeraCare shall
cooperate with each other reasonably and in good faith to determine a mutually
acceptable return position.

                (d) Subject to Section 2.1(c), to the extent an election, return
position, or amendment to a federal Income Tax Return filed by SeraCare or a
member of the SeraCare Consolidated Group relates to an item of income, gain,
loss or deduction of Life Sciences accruing in a Post-Distribution Taxable
Period, Life Sciences and SeraCare shall cooperate with

                                      -5-
<PAGE>

each other reasonably and in good faith to determine a mutually acceptable
election, return position, or amendment to such Income Tax Return.
Notwithstanding the foregoing, if such election, return position, or amendment
to such Income Tax Return solely affects Life Sciences, such election, return
position, or amendment to such Income Tax Return shall be determined by Life
Sciences in its sole discretion, reasonably and in good faith.

                (e) Cooperation. Life Sciences shall furnish SeraCare, at least
sixty (60) days before the due date (including extensions) of any SeraCare
Consolidated Federal Return, its completed section of such return, prepared in
accordance with this Agreement, and in a manner consistent with prior returns.
Life Sciences shall also furnish SeraCare work papers and other such information
and documentation as is reasonably requested by SeraCare with respect to Life
Sciences.

          Section 2.2  State and Local Returns of SeraCare.
                       -----------------------------------

                (a) General. SeraCare shall have sole and exclusive
                    -------
responsibility for the preparation and filing of all SeraCare State and Local
Returns. SeraCare shall on a timely basis file or cause to be filed all SeraCare
State and Local Returns and estimated tax returns of the SeraCare Consolidated
Group as are required to be filed in its sole discretion. SeraCare shall have
the right to: determine the manner in which all such returns shall be filed;
make any elections in connection with any such returns; contest, compromise and
settle any adjustments of deficiency proposed, asserted or assessed in
connection with any such returns; file, pursue, compromise or settle any claim
for refund; and determine whether any refunds to which the SeraCare Consolidated
Group is entitled shall be paid by way of a refund or credit. Notwithstanding
the foregoing, such returns shall be filed in a manner consistent with the
preparation of the relevant SeraCare Consolidated Federal Return and, when
requested by Life Sciences in its reasonable discretion, shall allocate items of
income, gain, loss and deduction of Life Sciences on a per diem basis.

                (b) Notwithstanding Section 2.2(c) and (d), SeraCare shall have
the sole authority to take any position on SeraCare State and Local Returns
(including any amended returns) to the extent that such position is consistent
with SeraCare's prior practice. To the extent such position on SeraCare State
and Local Returns is related to the Income Tax Liability of Life Sciences, Life
Sciences and SeraCare shall cooperate with each other reasonably and in good
faith to determine whether any such position is consistent with SeraCare's prior
practice, is inconsistent with SeraCare's prior practice, or has no comparable
prior practice.

                (c) SeraCare shall allow Life Sciences an opportunity to review
and comment upon such SeraCare State and Local Returns (including any amended
returns) to the extent that they relate to the Income Tax Liability of Life
Sciences solely to the extent that positions taken on such returns are
inconsistent with SeraCare's prior practice or have no comparable prior
practice. For any position on such SeraCare State and Local Returns that is
inconsistent with SeraCare's prior practice or has no comparable prior practice,
and that relates to the Income Tax Liability of Life Sciences that would affect
Life Sciences on or after the date hereof, Life Sciences and SeraCare shall
cooperate with each other reasonably and in good faith to determine a mutually
acceptable return position.

                                      -6-
<PAGE>

                (d) Subject to Section 2.2(c), to the extent an election, return
position, or amendment to a state or local Income Tax Return filed by SeraCare
or a member of the SeraCare Consolidated Group relates to an item of income,
gain, loss or deduction of Life Sciences accruing in a Post-Distribution Taxable
Period, Life Sciences and SeraCare shall cooperate with each other reasonably
and in good faith to determine a mutually acceptable election, return position,
or amendment to such Income Tax Return. Notwithstanding the foregoing, if such
election, return position, or amendment to such Income Tax Return solely affects
Life Sciences, such election, return position, or amendment to such Income Tax
Return shall be determined by Life Sciences in its sole discretion, reasonably
and in good faith.

                (e) Cooperation. SeraCare shall timely advise Life Sciences of
the inclusion of Life Sciences in any SeraCare State and Local Returns and the
jurisdictions in which such returns will be filed. Life Sciences shall evidence
its agreement to be included in such return on the appropriate form(s) and shall
take such other actions as may be appropriate to carry out the purposes and
intent of Section 2.1 and this Section 2.2, provided that such actions are not
inconsistent with this Agreement. Life Sciences shall furnish SeraCare, at least
sixty (60) days before the due date (including extensions) of any such SeraCare
State and Local Returns, its completed section of such returns, prepared in
accordance with this Agreement, and in a manner consistent with prior returns.
Life Sciences shall also furnish SeraCare workpapers and other such information
and documentation as is reasonably requested by SeraCare with respect to Life
Sciences.

          Section 2.3  Income Tax Liability.
                       --------------------

                (a) SeraCare Consolidated Federal Return Liability. Except to
                    ----------------------------------------------
the extent otherwise provided herein, SeraCare shall be liable for and indemnify
Life Sciences against all Income Taxes due in respect of all SeraCare
Consolidated Federal Returns.

                (b) SeraCare State and Local Return Liability. Except to the
                    -----------------------------------------
extent otherwise provided herein, SeraCare shall be liable for and indemnify
Life Sciences against all Income Taxes due in respect of all SeraCare State and
Local Returns.

                (c) Life Sciences Payment of Income Tax Liability. With respect
                    ---------------------------------------------
to the Pre-Distribution Taxable Period beginning the date hereof and ending on
the Distribution Date (the "Life Sciences Liability Period"), Life Sciences
shall pay to SeraCare an amount equal to the amount of taxes for which Life
Sciences would be directly liable if Life Sciences filed its Income Tax Returns
on a separate company basis and paid Income Tax based solely upon items of
income, gain, loss or deduction of Life Sciences for the Life Sciences Liability
Period (the "Life Sciences Tax Liability"). For purposes of determining the Life
Sciences Tax Liability, Life Sciences shall furnish SeraCare, at least sixty
(60) days before the due date (including extensions) of any relevant Income Tax
Return of SeraCare, its calculation of the items of income, gain, loss or
deduction of Life Sciences as a separate company, based upon a closing of the
books method. Life Sciences shall also furnish SeraCare work papers and other
such information and documentation as is reasonably requested by SeraCare with
respect to Life Sciences. In no event shall the Life Sciences Tax Liability
attributable to any SeraCare Consolidated Return Period exceed the aggregate
amount of Income Tax payable by SeraCare for such period.

                                      -7-
<PAGE>

          Section 2.4  Life Sciences Separate Returns and Income Tax Liability.
                       -------------------------------------------------------
Life Sciences shall prepare, or cause to be prepared, all Income Tax Returns of
Life Sciences for, and shall be liable for, all Income Taxes of Life Sciences
due in respect of, (a) all Post-Distribution Taxable Periods and (b) any taxable
period for which Life Sciences, with respect to such Income Tax, is not or was
not a member of the SeraCare Consolidated Group.

                                  ARTICLE III
                       INDEMNIFICATION FOR INCOME TAXES

          Section 3.1  Indemnification by SeraCare. Except as otherwise provided
                       ---------------------------
in this Article III, SeraCare shall indemnify and hold Life Sciences and its
successors and assigns harmless from and against (i) the SeraCare Consolidated
Tax Liability, including any Income Taxes that are imposed on SeraCare, any
member of the SeraCare Consolidated Group, Life Sciences or any other Person as
a result (in whole or in part) of the Distribution or the Merger, (ii) any
liability for Income Taxes as a result of Treasury Regulations ss.1.1502-6 or
any analogous or similar provision under state or local law or regulation, of
any Person which is or has ever been a member of the SeraCare Consolidated
Group, (iii) all Income Tax Liabilities that SeraCare is required to pay under
Article II hereof, and (iv) any costs and expenses related to any of the
foregoing (including, without limitation, reasonable legal, accounting,
appraisal, consulting or similar fees and expenses), provided, however, that
this Section 3.1 shall not apply to any portion of the Life Sciences Tax
Liability.

          Section 3.2  Indemnification by Life Sciences. From and after the
                       --------------------------------
Distribution Date, Life Sciences shall indemnify and hold each member of the
SeraCare Consolidated Group (other than Life Sciences) harmless from and against
(i) all Income Tax Liabilities that Life Sciences is required to pay under
Article II hereof, and (ii) any costs and expenses related to any of the
foregoing (including, without limitation, reasonable legal, accounting,
appraisal, consulting or similar fees and expenses.

                                  ARTICLE IV
                              INCOME TAX CONTESTS

          Section 4.1  Notification. Life Sciences shall promptly upon receipt
                       ------------
of notice thereof notify SeraCare in writing of any communication with respect
to any pending or threatened Proceeding in connection with an Income Tax
Liability (or an issue related thereto) for which SeraCare may be responsible
pursuant to this Agreement. Life Sciences shall include with such notification a
true, correct and complete copy of any written communication, and an accurate
and complete written summary of any oral communication, so received by Life
Sciences. The failure of Life Sciences to timely forward such notification in
accordance with the immediately preceding sentence shall not relieve SeraCare of
its obligation to pay such Income Tax Liability or indemnify Life Sciences
therefor, except and to the extent that the failure to timely forward such
notification actually prejudices the ability of SeraCare to contest such Income
Tax Liability or increases the amount of such Income Tax Liability. Similarly,
SeraCare shall promptly upon receipt of notice thereof notify Life Sciences in
writing of any communication with respect to any pending or threatened
Proceeding in connection with an Income Tax Liability (or an issue related
thereto) for which Life Sciences may be responsible pursuant to this Agreement.
SeraCare shall include with such notification a true, correct and complete copy
of any written

                                      -8-
<PAGE>

communication, and an accurate and complete written summary of any oral
communication, so received by SeraCare. The failure of SeraCare to timely
forward such notification in accordance with the immediately preceding sentence
shall not relieve Life Sciences of its obligation to pay such Income Tax
Liability or indemnify SeraCare therefor, except and to the extent that the
failure to timely forward such notification actually prejudices the ability of
Life Sciences to contest such Income Tax Liability or increases the amount of
such Income Tax Liability.

          Section 4.2  Proceedings Involving SeraCare. Except as limited in
                       ------------------------------
Section 4.2(a), (b), (c), and (d), SeraCare (or such member of the SeraCare
Consolidated Group as SeraCare shall designate) shall be entitled to designate
counsel with respect to any Proceeding with respect to an Income Tax Return
filed by SeraCare or a member of the SeraCare Consolidated Group, and SeraCare
shall have the right to resolve any such Proceeding in its sole discretion.

                (a) SeraCare shall allow Life Sciences and its counsel to
participate at its own expense in any Proceeding relating to an Income Tax
Return filed for a SeraCare Consolidated Return Period, to the extent that such
Proceeding relates to Income Tax for which Life Sciences would be liable under
Sections 2.3 or 2.4 hereof. Life Sciences shall have the sole authority to
determine whether any such Proceeding relates to Income Tax for which Life
Sciences would be liable under Sections 2.3 or 2.4 hereof, which authority shall
be exercised by Life Sciences reasonably and in good faith;

                (b) Subject to Section 4.2(a), to the extent an election, return
position, or amendment to an Income Tax Return filed by SeraCare or a member of
the SeraCare Consolidated Group relates to an item of income, gain, loss or
deduction of Life Sciences accruing in a Post-Distribution Taxable Period, Life
Sciences and SeraCare shall cooperate with each other reasonably and in good
faith to determine a mutually acceptable election, return position, or amendment
to such Income Tax Return. Notwithstanding the foregoing, if such election,
return position, or amendment to such Income Tax Return solely affects Life
Sciences, such election, return position, or amendment to such Income Tax Return
shall be determined by Life Sciences in its sole discretion reasonably and in
good faith;

                (c) Life Sciences shall be entitled to designate counsel with
respect to any Proceeding with respect to an Income Tax Return that includes
solely Life Sciences and relates solely to items for which Life Sciences is
responsible hereunder, and Life Sciences shall have the right to resolve any
such Proceedings in its sole discretion.

                (d) Life Sciences shall allow SeraCare and its counsel to
participate at its own expense in any Proceeding relating to an Income Tax
Return filed by Life Sciences, to the extent that such Proceeding relates to
Income Tax for which SeraCare would be liable under Section 2.3 hereof. SeraCare
shall have the sole authority to determine whether any such Proceeding relates
to Income Tax for which SeraCare would be liable under Section 2.3 hereof, which
authority shall be exercised by SeraCare reasonably and in good faith.

          Section 4.3  Power of Attorney. Life Sciences shall execute and
                       -----------------
deliver to SeraCare any power of attorney or other document reasonably requested
by SeraCare (or a designee) in connection with any Proceeding described in
Section 4.2 hereof.

                                      -9-
<PAGE>

                                   ARTICLE V
            APPORTIONMENT OF TAX ATTRIBUTES; REFUNDS; TAX SHARING
                                  AGREEMENTS

          Section 5.1  Apportionment of Tax Attributes.
                       -------------------------------

                (a) If the SeraCare Consolidated Group has a Pre-Distribution
Tax Attribute, the portion, if any, of such Pre-Distribution Tax Attribute that
shall be apportioned to Life Sciences and treated as a carryover to the first
Post-Distribution Taxable Period of Life Sciences shall be determined as if the
members of the SeraCare Consolidated Group had filed returns on a separate
company basis; provided, however, that the portion, if any, of any consolidated
unused foreign tax credit which shall be apportioned to Life Sciences shall be
determined separately with respect to each of the items of income listed in
Section 904(d) of the Code.

                (b) Subject to Life Sciences' consent, which consent shall not
be unreasonably withheld, SeraCare shall determine the portion, if any, of any
Pre-Distribution Tax Attribute that must (absent a Final Determination to the
contrary) be apportioned to Life Sciences in accordance with this Section 5.1
and applicable law, and the amount of tax basis and earnings and profits to be
apportioned to Life Sciences in accordance with applicable law, and shall
provide written notice of the calculation thereof to Life Sciences within 180
days of the filing of the SeraCare Consolidated Federal Return that includes the
Distribution Date.

          Section 5.2  Refunds. Except as set forth in this Section 5.2 and in
                       -------
Section 5.3, SeraCare shall be entitled to all Refunds (and any interest thereon
received from the applicable Taxing Jurisdiction) in respect of Income Taxes for
all SeraCare Consolidated Returns. Life Sciences shall be entitled to all
Refunds (and any interest thereon received from the applicable Taxing
Jurisdiction) in respect of (a) Income Taxes paid by Life Sciences for all Post-
Distribution Taxable Periods, (b) the Life Sciences Tax Liability, and (c) any
separate returns filed by Life Sciences pursuant to Section 2.4 hereof. A party
receiving a Refund to which another party is entitled pursuant to this Section
5.2 shall pay the amount to which such other party is entitled within ten (10)
days after such Refund is received. SeraCare shall be permitted to file, and
Life Sciences shall fully cooperate with SeraCare in connection with, any claim
for Refund in respect of an Income Tax for which any member of the SeraCare
Consolidated Group is responsible pursuant to Article II hereof.

          Section 5.3  Carrybacks. Life Sciences elects not to carry back any
                       ----------
Post-Distribution Tax Attribute into a SeraCare Consolidated Return. SeraCare
shall have no obligation to file any Income Tax Return or refund claim, amended
or otherwise, as a result of any Post-Distribution Tax Attribute of Life
Sciences.

          Section 5.4  Retention of Carryovers. SeraCare shall not elect to
                       -----------------------
retain any net operating loss carryovers or capital loss carryovers of Life
Sciences under Treasury Regulations ss. 1.1502-20(g), provided, however, that
any such net operating loss carryover or capital loss carryover of Life Sciences
may be used in the computation of the taxable income of any SeraCare
Consolidated Return.

                                     -10-
<PAGE>

          Section 5.5  Tax Sharing Agreements. Any tax sharing agreement (other
                       ----------------------
than this Agreement) between SeraCare and Life Sciences or between Life Sciences
and any other Person shall be terminated as of the Distribution Date and will
have no further effect for any taxable year (whether the current year, a future
year, or a past year).

                                  ARTICLE VI
                    COOPERATION AND EXCHANGE OF INFORMATION

          Section 6.1  Cooperation.
                       -----------

                (a) Life Sciences, on behalf of itself and each of its
affiliates, agrees to provide SeraCare (or its designee) with such cooperation
or information as SeraCare (or its designee) reasonably shall request in
connection with the determination of any other calculations described in this
Agreement, the preparation or filing of any Income Tax Return or claim for
Refund, or the conduct of any Proceeding. Such cooperation and information shall
include, without limitation, (i) promptly forwarding copies of appropriate
notices and forms or other communications (including, without limitation,
information document requests, revenue agent reports and similar reports,
notices of proposed adjustments and notices of deficiency) received from or sent
to any Taxing Jurisdiction or any other administrative, judicial or governmental
authority, (ii) upon reasonable notice, providing copies of all relevant Income
Tax Returns, together with accompanying schedules and related workpapers,
documents relating to rulings or other determinations by taxing authorities, and
such other records concerning the ownership and tax basis of property, or other
relevant information that Life Sciences or its affiliates may possess, (iii)
upon reasonable notice, providing of such additional information and
explanations of documents and information provided under this Agreement
(including statements, certificates and schedules delivered by either party) as
shall be reasonably requested by SeraCare (or its designee), (iv) upon
reasonable notice, the providing of any document that may be necessary or
reasonably helpful in connection with the filing of an Income Tax Return, a
claim for a Refund, or in connection with any Proceeding, including such
waivers, consents or powers of attorney as may be necessary for SeraCare to
exercise its rights under this Agreement, and (v) upon reasonable notice, using
reasonable efforts to obtain any documentation from a governmental authority or
a third party that may be necessary or reasonably helpful in connection with any
of the foregoing. Upon reasonable notice, Life Sciences shall make its, or shall
cause its affiliates to make their, employees and facilities available on a
mutually convenient basis to provide explanation of any documents or information
provided hereunder. Any information obtained under this Section 6.1(a) shall be
kept confidential, except as otherwise reasonably may be necessary in connection
with the filing of Income Tax Returns or claims for Refund or in conducting any
Proceeding. It is expressly the intention of the parties to this Agreement to
take all actions that shall be necessary to establish SeraCare as the sole agent
for Income Tax purposes with respect to all SeraCare Consolidated Returns.

                (b) SeraCare, on behalf of itself and each member of the
SeraCare Consolidated Group (including SeraCare), agrees to provide Life
Sciences (or its designee) with such cooperation or information as Life Sciences
(or its designee) reasonably shall request in connection with the determination
of any other calculations described in this Agreement, the preparation or filing
of any Income Tax Return or claim for Refund, or the conduct of any

                                     -11-
<PAGE>

Proceeding. Such cooperation and information shall include, without limitation
and upon reasonable notice, promptly forwarding copies of appropriate notices
and forms or other communications (including, without limitation, information
document requests, revenue agent's reports and similar reports, notices of
proposed adjustments and notices of deficiency) received from or sent to any
Taxing Jurisdiction or any other administrative, judicial or governmental
authority, (ii) upon reasonable notice, providing copies of all relevant Income
Tax Returns, together with accompanying schedules and related workpapers,
documents relating to rulings or other determinations by taxing authorities, and
such other records concerning the ownership and tax basis of property, or other
relevant information that SeraCare or any member of the SeraCare Consolidated
Group may possess, (iii) upon reasonable notice, the provision of such
additional information and explanations of documents and information provided
under this Agreement (including statements, certificates and schedules delivered
by either party) as shall be reasonably requested by Life Sciences (or its
designee), (iv) upon reasonable notice, the execution of any document that may
be necessary or reasonably helpful in connection with the filing of an Income
Tax Return, a claim for a Refund, or in connection with any Proceeding,
including such waivers, consents or powers of attorney as may be necessary for
Life Sciences to exercise its rights under this Agreement, and (v) the use of
SeraCare's reasonable efforts to obtain any documentation from a governmental
authority or a third party that may be necessary or reasonably helpful in
connection with any of the foregoing. Upon reasonable notice, SeraCare shall
make, or shall cause each member of the SeraCare Consolidated Group to make, its
employees and facilities available on a mutually convenient basis to provide
explanation of any documents or information provided hereunder. Any information
obtained under this Section 6.1(b) shall be kept confidential, except as
otherwise reasonably may be necessary in connection with the filing of Income
Returns or claims for Refund or in conducting any Proceeding. Notwithstanding
any other provision of this Agreement, neither Life Sciences, nor any of its
affiliates nor any other Person shall have any right to receive or obtain any
information relating to income of SeraCare or any of its affiliates other than
information relating to items of income, gain, loss, deduction, or the Income
Tax Liability of Life Sciences.

          Section 6.2  Retention of Records. Life Sciences agrees to retain all
                       --------------------
Income Tax Returns, related schedules and workpapers, and all material records
and other documents as required under Code Section 6001 and the regulations
promulgated thereunder (and any similar provision of state, local, or foreign
Income or other Tax law) existing on the date hereof or created in respect of
(i) any taxable period that ends on or before or includes the Distribution Date
or (ii) any taxable period that may be subject to a claim hereunder, until the
later of (x) the expiration of the statute of limitations (including extensions)
for the taxable periods to which such Income Returns and other documents relate
and (y) the Final Determination of any payments that may be required in respect
of such taxable periods under this Agreement. From and after the end of the
period described in the preceding sentence of this Section 6.2, if Life Sciences
wishes to dispose of any such records and documents, then Life Sciences shall
provide written notice thereof to SeraCare and shall provide SeraCare the
opportunity to take possession of any such records and documents within ninety
(90) days after such notice is delivered; provided, however, that if SeraCare
does not, within such ninety (90) day period, confirm its intention to take
possession of such records and documents, Life Sciences may destroy or otherwise
dispose of such records and documents.

                                     -12-
<PAGE>

                                  ARTICLE VII
                                   PAYMENTS

          Section 7.1  Method of Payment. All payments required by this
                       -----------------
Agreement shall be made by (a) wire transfer to the appropriate bank account as
may from time to time be designated by the parties for such purpose; provided
that, on the date of such wire transfer, notice of the transfer is given to the
recipient thereof in accordance with Section 8.4 hereof, or (b) any other method
agreed to by the parties. All payments due under this Agreement shall be deemed
to be paid when available funds are actually received by the payee.

          Section 7.2  Interest. Any payment required by this Agreement that is
                       --------
not made on or before the date required hereunder shall bear interest, from and
after such date through the date of payment, at the underpayment rate as in
effect at such time under Section 6621 of the Code.

          Section 7.3  Characterization of Payments. For all tax purposes, the
                       ----------------------------
parties hereto agree to treat, and to cause their respective affiliates to
treat, (i) any payment required by this Agreement as a contribution by SeraCare
to Life Sciences occurring immediately prior to the Distribution and (ii) any
payment of interest or non-federal Income Taxes by or to a Taxing Jurisdiction,
as taxable to or deductible by, as the case may be, the party entitled under
this Agreement to receive such payment or required under this Agreement to make
such payment, in either case except as otherwise mandated by applicable law;
provided that in the event it is determined as a result of a Final Determination
that any such treatment is not permissible, the payment in question shall be
adjusted to place the parties in the same after-tax position they would have
enjoyed absent such Final Determination. Any payment required by this Agreement
by Life Sciences to SeraCare shall be treated as Life Sciences' share of the tax
liability of the SeraCare Consolidated Returns, as determined in accordance with
this Agreement and the Treasury Regulations under Section 1502.

          Section 7.4  Time of Indemnification Payment. To the extent an
                       -------------------------------
indemnification obligation arises, the Indemnifying Party shall, upon at least
ten (10) days' prior notice, make payment pursuant to such indemnification
obligation no later than five (5) days prior to the date the Indemnified Party
makes a payment of taxes, interest, or penalties with respect to such Income Tax
Liability, including a proposed adjustment of taxes or an assessment of tax
deficiency asserted or made by any Taxing Jurisdiction that is premised in whole
or part on such Income Tax Liability, or a payment made in settlement of an
asserted tax deficiency.

                                 ARTICLE VIII
                           MISCELLANEOUS PROVISIONS

          Section 8.1  Entire Agreement. This Agreement, the Ancillary
                       ----------------
Agreements and the Exhibits and Schedules referenced or attached hereto and
thereto, constitute the entire agreement between the parties with respect to the
subject matter hereof and shall supersede all prior written and oral and all
contemporaneous oral agreements and understandings with respect to the subject
matter hereof.

          Section 8.2  Dispute Resolution. Any and all controversies, disputes
                       ------------------
or claims arising out of, relating to, in connection with or resulting from this
Agreement (or any

                                     -13-
<PAGE>

amendment thereto or any transaction contemplated hereby or thereby), including
as to its existence, interpretation, performance, non-performance, validity,
breach or termination, including any claim based on contract, tort, statute or
constitution and any claim raising questions of law, whether arising before or
after termination of this Agreement, shall be deemed a Dispute as defined in
Section 7.6 of the Separation Agreement and shall be resolved exclusively by, in
accordance with, and subject to the limitations set forth in Section 7.6 of the
Separation Agreement.

          Section 8.3  Governing Law. This Agreement shall be governed by and
                       -------------
construed in accordance with the laws of the State of Delaware, without regard
to its rules regarding conflicts of laws.

          Section 8.4  Notices. Any notice, demand, offer, request or other
                       -------
communication required or permitted to be given by either party pursuant to the
terms of this Agreement shall be in writing and shall be deemed effectively
given the earlier of (i) when received, (ii) when delivered personally, (iii)
one (1) business day after being delivered by facsimile (with receipt of
appropriate confirmation), (iv) one (1) business day after being deposited with
an overnight courier service, or (v) four (4) days after being deposited in the
U.S. mail, First Class with postage prepaid, and addressed to the attention of
the party's Chief Executive Officer at the address of its principal executive
office or such other address as a party may request by notifying the other party
thereof in writing.

          Section 8.5  Agent. Life Sciences hereby irrevocably appoints SeraCare
                       -----
as its agent and limited attorney-in-fact to take any action as SeraCare may
deem necessary or appropriate to effect the tax sharing contemplated by this
Agreement including, without limitation, those actions specified in Treasury
Regulation ss.1.1502-77(a) and analogous provisions of state and local law.

          Section 8.6  Amendment. This Agreement may be amended, modified or
                       ---------
supplemented only by a written agreement signed by both of the parties hereto.

          Section 8.7  Counterparts. This Agreement and the other documents
                       ------------
referred to herein, may be executed via facsimile or otherwise in counterparts,
each of which shall be deemed to be an original but all of which shall
constitute one and the same agreement.

          Section 8.8  Binding Effect; Assignment. This Agreement shall inure to
                       --------------------------
the benefit of and be binding upon the parties hereto and their respective legal
representatives and successors, and nothing in this Agreement, express or
implied, is intended to confer upon any other Person any rights or remedies of
any nature whatsoever under or by reason of this Agreement. Except as herein
specifically provided to the contrary, neither party may assign this Agreement
or any rights or obligations hereunder, without the prior written consent of the
other party, and any such assignment shall be void; provided, however, that
either party (or its permitted successive assignees or transferees hereunder)
may assign or transfer this Agreement as a whole without consent to an entity
that succeeds to all or substantially all of the business or assets of such
party to which this Agreement relates. Notwithstanding the foregoing, SeraCare
may assign any of its rights or obligations under this Agreement to any member
of its consolidated group as determined under Section 1504 of the Code it shall
designate or to any

                                     -14-
<PAGE>

purchaser of SeraCare; provided, however, that no such assignment shall relieve
SeraCare of any obligation to make a payment hereunder to Life Sciences to the
extent such designee fails to make such payment.

          Section 8.9  Severability. The parties hereto have negotiated and
                       ------------
prepared the terms of this Agreement in good faith with the intent that each and
every one of the terms, covenants and conditions herein be binding upon and
inure to the benefit of the respective parties. Accordingly, if any one or more
of the terms, provisions, promises, covenants or conditions of this Agreement or
the application thereof to any person or circumstance shall be adjudged to any
extent invalid, unenforceable, void or voidable for any reason whatsoever by a
court of competent jurisdiction, such provision shall be as narrowly construed
as possible, and each and all of the remaining terms, provisions, promises,
covenants and conditions of this Agreement or their application to other persons
or circumstances shall not be affected thereby and shall be valid and
enforceable to the fullest extent permitted by law. To the extent this Agreement
is in violation of applicable law, then the parties agree to negotiate in good
faith to amend the Agreement, to the extent possible consistent with its
purposes, to conform to law.

          Section 8.10 Waiver of Breach. The waiver by either party hereto of a
                       ----------------
breach or violation of any provision of this Agreement shall not operate as, or
be construed to constitute, a waiver of any subsequent breach of the same or
another provision hereof.

          Section 8.11 Amendment and Execution. This Agreement and amendments
                       -----------------------
hereto shall be in writing and executed in multiple copies via facsimile or
otherwise on behalf of SeraCare and Life Sciences by their respective duly
authorized officers and representatives. Each multiple copy shall be deemed an
original, but all multiple copies together shall constitute one and the same
instrument.

          Section 8.12 Authority. Each of the parties hereto represents to the
                       ---------
other that (a) it has the corporate or other requisite power and authority to
execute, deliver and perform this Agreement, (b) the execution, delivery and
performance of this Agreement by it have been duly authorized by all necessary
corporate or other actions, (c) it has duly and validly executed and delivered
this Agreement, and (d) this Agreement is a legal, valid and binding obligation,
enforceable against it in accordance with its terms subject to applicable
bankruptcy, insolvency, reorganization, moratorium or other similar laws
affecting creditors' rights generally and general equity principles.

          Section 8.13 Descriptive Headings. The headings contained in this
                       --------------------
Agreement and in the table of contents to this Agreement are for reference
purposes only and shall not affect in any way the meaning or interpretation of
this Agreement. When a reference is made in this Agreement to an Article or a
Section, such reference shall be to an Article or Section of this Agreement
unless otherwise indicated.

          Section 8.14 Gender and Number. Whenever the context of this Agreement
                       -----------------
requires, the gender of all words herein shall include the masculine, feminine
and neuter, and the number of all words herein shall include the singular and
plural.

                                     -15-
<PAGE>

          Section 8.15 Additional Assurances. Except as may be specifically
                       ---------------------
provided herein to the contrary, the provisions of this Agreement shall be self-
operative and shall not require further agreement by the parties; provided,
however, at the request of either party, the other party shall execute such
additional instruments and take such additional acts as are reasonable, and as
the requesting party may reasonably deem necessary, to effectuate this
Agreement.

          Section 8.16 Force Majeure. Neither party shall be liable or deemed to
                       -------------
be in default for any delay or failure in performance under this Agreement or
other interruption of service deemed to result, directly or indirectly, from
acts of God, civil or military authority, acts of public enemy, war, accidents,
explosions, earthquakes, floods, failure of transportation, strikes or other
work interruptions by either party's employees, or any other similar cause
beyond the reasonable control of either party unless such delay or failure in
performance is expressly addressed elsewhere in this Agreement.

                                     -16-
<PAGE>

         IN WITNESS WHEREOF, each of the parties has caused this Agreement to be
executed on its behalf by its officers thereunto duly authorized on the day and
year first above written.

SERACARE, INC.                                SERACARE LIFE SCIENCES, INC.

By: /s/ Barry Plost                           By:  /s/ Jerry Burdick
    ---------------------                          -----------------------
Name; Barry Plost                             Name; Jerry Burdick
Title: Chief Executive Officer                Title: Executive Vice President

                   [SIGNATURE PAGE TO TAX SHARING AGREEMENT]

                                     -17-<PAGE>

                                                                   EXHIBIT 10.13

                                                                REDACTED VERSION

                         SUPPLY AND SERVICES AGREEMENT

     *** Confidential treatment has been requested as to certain portions
     of this agreement. Such omitted confidential information has been
     designated by an asterisk and has been filed separately with the
     Securities and Exchange Commission pursuant to Rule 24b-2 under the
     Securities Exchange Act of 1934, as amended, and the Commission's
     rules and regulations promulgated under the Freedom of Information
     Act, pursuant to a request for confidential treatment. ***

          This Supply and Services Agreement (this "Agreement") is entered into
as of ___________,  2001, by and between SeraCare, Inc., a Delaware corporation
("SeraCare"), and SeraCare Life Sciences, Inc., a California corporation and
wholly-owned subsidiary of SeraCare ("Life Sciences").  SeraCare and Life
Sciences are sometimes referred to herein individually as a "party" or
collectively as the "parties."

                                RECITALS

          WHEREAS, SeraCare has entered into an Agreement and Plan of Merger
(the "Merger Agreement") with Instituto Grifols, S.A., a company organized under
the laws of Spain ("Grifols"), pursuant to which SeraCare will merge with and
into SI Merger Corp., a Delaware corporation and wholly-owned subsidiary of
Grifols (the "Merger"), provided that all of the conditions precedent to the
Merger set forth in the Merger Agreement have been satisfied;

          WHEREAS, the parties have determined that it is appropriate and
desirable to distribute to the holders of SeraCare's common stock, by means of a
pro rata distribution immediately prior to the effective time of the Merger, all
of the shares of Life Sciences common stock (the "Distribution");

          WHEREAS, the parties desire to set forth herein terms and conditions
pursuant to which SeraCare agrees to supply, and Life Sciences agrees to
purchase and accept, certain plasma products, and SeraCare agrees to perform
certain plasmapheresis services on referred donors, and Life Sciences agrees to
purchase and accept such referred donor plasma, following the Distribution.

          NOW, THEREFORE, in consideration of the foregoing and the mutual
covenants and agreements set forth below, the parties, intending to be legally
bound, hereby agree as follows:

  1.      Products, Services Prices and Payment
          -------------------------------------

          1.1  Life Sciences agrees to purchase from SeraCare, and SeraCare
agrees to sell to Life Sciences, plasma-related products (the "Products") set
forth on Exhibit A attached hereto at such prices as set forth on Exhibit A.
         ---------
Life Sciences and SeraCare represent and warrant
<PAGE>

that such prices were determined as a result of arms-length negotiation between
the parties. The parties shall negotiate annually in good faith mutually
acceptable price adjustments (increase or decrease) of the Products based on
factors the parties deem relevant including the then prevailing market price for
such products, regulatory issues and testing requirements. Such price adjustment
shall be effective upon each anniversary of the initial, or any renewal term, of
this Agreement, provided that in the event that there are changes in any legal
or regulatory requirements that materially impact SeraCare's costs of the
Product production, the parties shall, prior to such annual negotiations,
negotiate in good faith price increases or decreases not to exceed the direct
costs of such change in legal or regulatory requirements, provided further that
in no event shall the price for the Products exceed the fair market value for
the Products. If the parties are unable to reach agreement on an annual price
adjustment as provided for herein, then the parties shall submit the matter to
dispute resolution as provided for in Section 8.5.

          1.2  Subject to Life Sciences' Standard Operating Procedures and any
applicable requirements relating to a subject donor's medical condition,
SeraCare agrees it shall  (i) perform automated plasmapheresis bleedings on all
donors referred by Life Sciences (the "Plasmapheresis Services"), and that Life
Sciences shall have the right to receive all blood plasma collected by SeraCare
which is derived from such referred donors (the "Referred Donor Plasma"), and
(ii) if and when SeraCare acquires an appropriately licensed and equipped
center, draw blood on all donors referred by Life Sciences (the "Blood Drawing
Services"), and that Life Sciences shall have the right to receive all whole
blood, off the clot, serum, et. al. therefrom (the "Referred Donor Blood,"
collectively, with the Referred Donor Plasma, the "Referred Donor Products.")
SeraCare shall conduct viral marker testing and FDA required confirmatory
testing on all Referred Donor Products (the "Testing Services").  The price,
including softgoods, (but excluding donor fees which shall be payable by Life
Sciences) for such Plasmapheresis Services, Blood Drawing Services, Testing
Services and Referred Donor Products (collectively, the "Referred Donor
Services") shall be as set forth on Exhibit A , as amended from time to time in
accordance with this Agreement.  Life Sciences and SeraCare represent and
warrant that such prices were determined as a result of arms-length negotiation
between the parties.  The parties shall negotiate annually in good faith
mutually acceptable price adjustments (increase or decrease) of the Referred
Donor Services based on factors the parties deem relevant including the then
prevailing market price for such products, regulatory issues and testing
requirements.  Such price adjustment shall be effective upon each anniversary
date of the initial, or any renewal term, of this Agreement, provided that in
the event that there are changes in any legal or regulatory requirements that
materially impact SeraCare's costs of the Referred Donor Services, the parties
shall, prior to such annual negotiations, negotiate in good faith price
increases or decreases not to exceed the direct costs of such change in legal or
regulatory requirements, provided further that in no event shall the price for
the Referred Donor Services exceed the fair market value for the Referred Donor
Services.  If the parties are unable to reach agreement on an annual price
adjustment as provided for herein, then the parties shall submit the matter to
dispute resolution as provided for in Section 8.5.

          1.3  Payment by Life Sciences for any Products will be made within
thirty (30) days from date of delivery of such Products by SeraCare, and payment
by Life Sciences for any Referred Donor Services will be made within thirty (30)
days from the date of delivery of the Referred Donor Products by SeraCare.

                                      -2-
<PAGE>

          1.4   All costs of shipment, freight, insurance and all government
taxes and duties incurred in connection with shipment of the Products and the
Referred Donor Products to Life Sciences or Life Sciences customers will be paid
by Life Sciences.

          1.5   Life Sciences agrees that it shall exclusively use the
appropriately licensed Centers (as hereinafter defined) for donors in respect of
Referred Donor Services for all donors who reside within reasonable proximity to
an appropriately licensed Center.

     2.   Delivery, Storage and Handling
          ------------------------------

          2.1   All Products and Referred Donor Products will be packed and
shipped in accordance with SeraCare's established Standard Operating Procedures
that significantly relate to the collection of blood plasma in effect as of the
date hereof, as may be amended from time to time as provided for in Section 3.1,
and all applicable sections of the Code of Federal Regulations, including all
applicable sections and regulations issued or promulgated by the United States
Food and Drug Administration, as well as any other applicable federal, state,
and local regulations concerning the collection, packaging, processing, storing
or shipping of the Products. All shipments of the Products and Referred Donor
Products will contain all duly and properly prepared documentation required by
applicable laws or regulations.

          2.2   Life Sciences shall deliver to SeraCare a purchase order with
the specifications of each order of the Products.

          2.3   Title and all risk of loss and damage regarding the Products and
the Referred Donor Products shall pass to Life Sciences upon delivery to Life
Sciences, except for Products or Referred Donor Products rejected pursuant to
Section 3.3.

          2.4   Life Sciences agrees that upon delivery of Products and Referred
Donor Products to Life Sciences, Life Sciences shall handle, store and maintain
all Products and Referred Donor Products in an appropriate environment in
accordance with applicable law, industry standards and good manufacturing
practices. If Life Sciences shall fail to handle, store and maintain any
Products or Referred Donor Products in accordance with this Agreement, such
Products or Referred Donor Products shall not be subject to rejection as
provided below. Life Sciences shall indemnify SeraCare pursuant to Section 8.1
hereof in the event that any third-party claims arise because of any failure by
Life Sciences to handle, store and maintain Products or Referred Donor Products
in accordance with this Agreement.

     3.   Product Quality and Use
          -----------------------

          3.1   All Products sold to Life Sciences hereunder shall conform to
the quality and technical specifications set forth for such Products on Exhibit
                                                                        -------
B attached hereto (the "Minimum Specifications"), provided that SeraCare may
-
modify its Standard Operating Procedures (which are included in the Minimum
Specifications) only if such modification (i) relates solely to a change
required by law (based on the advice of nationally recognized healthcare
regulatory counsel) and SeraCare notifies Life Sciences of such modification at
least five business days prior to the effective date of such modification, (ii)
does not significantly relate to the collection of blood plasma, or (iii) is not
required by law (based on the advice of nationally recognized healthcare
regulatory counsel) and SeraCare has obtained written consent

                                      -3-
<PAGE>

of such change from Life Sciences. In addition, SeraCare agrees that the
Products delivered to Life Sciences shall not be misbranded or adulterated
within the meaning of the Federal Food, Drug and Cosmetic Act, and shall be in
full compliance with the Biological Products Section of the Public Health
Service Act, and applicable regulations, and shall be in full compliance with
any applicable international, federal, state or local laws, ordinances or
regulations in accordance with past practice. Subject to Section 8.14 hereof, in
the event SeraCare ships to Life Sciences any Products which are not in
compliance with such laws, regulations or the Minimum Specifications, then
SeraCare will be liable to Life Sciences for damages arising out of relating to
such non-compliant Products (including, without limitation, attorneys fees,
arbitrators' fees, costs of experts and court costs).

          3.2   All Referred Donor Services performed hereunder shall conform to
the quality and technical specifications set forth for such Referred Donor
Services on Exhibit C attached hereto (the "Referred Donor Minimum
            ---------
Specifications"), provided that Life Sciences may modify the Minimum
Specifications upon written notification to SeraCare with such modifications to
be effective within five (5) business days of delivery of such notification.  In
addition, SeraCare agrees that the Referred Donor Products delivered to Life
Sciences shall not be misbranded or adulterated within the meaning of the
Federal Food, Drug and Cosmetic Act, and shall be in full compliance with the
Biological Products Section of the Public Health Service Act, and applicable
regulations, and shall be in full compliance with any applicable international,
federal, state or local laws, ordinances or regulations in accordance with past
practice.  Subject to Section 8.14 hereof,  in the event SeraCare ships to Life
Sciences any Referred Donor Products which is not in compliance with such laws,
regulations or the Referred Donor Minimum Specifications, then SeraCare will be
liable to Life Sciences for damages arising out of relating to such non-
compliant Referred Donor Products (including, without limitation, attorneys
fees, arbitrators' fees, costs of experts and court costs).

          3.3

          (A)   All Referred Donor Products furnished by SeraCare to Life
Sciences hereunder which does not meet the Referred Donor Minimum
Specifications, and all Products furnished by SeraCare to Life Sciences
hereunder which do not meet the Minimum Specifications, or which are, in Life
Sciences' reasonable judgment, otherwise defective shall be subject to rejection
notwithstanding prior payment by Life Sciences, provided that any rejection of
Referred Donor Products or Products, other than de minimis rejections, shall be
accompanied by a written explanation from Life Sciences setting forth the basis
or bases for such rejection. SeraCare acknowledges and agrees that Life Sciences
may reject any Products that do not conform to the Minimum Specifications, or
any Referred Donor Products that does not conform to the Referred Donor Minimum
Specifications, at any time up to thirty (30) business days after delivery of
such Products or Referred Donor Products to Life Sciences or Life Sciences
customers, provided that any Products or Referred Donor Products not rejected
during such period shall be deemed to be accepted by Life Sciences.

          (B)   Subject to Section 2.4 and 8.14 hereof, Life Sciences shall have
no liability whatsoever with respect to such rejected Products or Referred Donor
Products and SeraCare shall reimburse Life Sciences for any and all costs and
expenses (including but not limited to shipment, freight, insurance and all
government taxes and duties incurred during

                                      -4-
<PAGE>

shipment, transportation, storage, handling and pooling costs) which are
incurred by Life Sciences with respect to any such rejected Products or Referred
Donor Products. SeraCare shall have the right to instruct Life Sciences to (i)
return any rejected Products or Referred Donor Products to SeraCare (after
receiving notification of such rejection) or (ii) destroy such rejected Products
or Referred Donor Products in lieu of returning them to SeraCare, provided that
Life Sciences shall use its best efforts to dispose of such rejected Products or
Referred Donor Products in accordance with all applicable law and regulations.
In the event SeraCare does not give instructions regarding the disposition of
such rejected Products or Referred Donor Products within fifteen (15) business
days after notice of rejection of the Products or Referred Donor Products by
Life Sciences to SeraCare, Life Sciences shall have the right to destroy or
otherwise dispose of all such rejected Products or Referred Donor Products at
SeraCare's sole expense without any liability whatsoever to SeraCare and without
obligation to compensate SeraCare for any part of such rejected Products or
Referred Donor Products.

          3.4   Subject to the terms and conditions contained herein, including
without limitation the liability limitation in Section 8.14, in the event Life
Sciences makes prior payment for Products or Referred Donor Products which are
later rejected in accordance with this Agreement, the purchase price of such
rejected Products or Referred Donor Products, and any other costs and expenses
incurred by Life Sciences in connection with such rejected Products or Referred
Donor Products, may be set off or deducted from any other payments due to
SeraCare from Life Sciences.  In addition, Life Sciences shall have the right,
at its sole election, to demand reimbursement, in cash, for the purchase price
and any other sums paid in connection with any such rejected Products or
Referred Donor Services, subject to SeraCare's right to set off or deduct
payments due from Life Sciences.

          3.5   Life Sciences represents and warrants to SeraCare that the
Products and the Referred Donor Products shall be manufactured and distributed
solely for diagnostic purposes and not for human consumption or otherwise for
injection into humans.

     4.   Regulatory Requirements
          -----------------------

          4.1   SeraCare represents and warrants that as of the date of this
Agreement, each of the centers set forth on Exhibit D attached hereto, as
                                            ---------
amended from time to time in accordance herewith, (the "Centers" or individually
a "Center") is Licensed as hereinafter defined.  For purposes of this Agreement,
a Center is Licensed when it has (i) a license issued by the United States Food
and Drug Administration (the "FDA"); (ii) is Quality Plasma Program ("QPP")
certified, and (iii) has all other material permits and licenses which are
required by federal, state or local regulatory agencies in order for SeraCare to
operate the Centers, except for the Centers located in Danville, Virginia and
Providence, Rhode Island, for which SeraCare agrees to use its best efforts to
obtain QPP certification.  SeraCare agrees that all of the Products sold by
SeraCare to Life Sciences hereunder will be collected only at the Centers, and
all of the Referred Donor Services will be performed only at the Centers.
SeraCare shall immediately notify Life Sciences if any Center is no longer
Licensed, and the parties expressly agree that any Center that is no longer
Licensed will be deleted from Exhibit D.

          4.2   SeraCare agrees that it shall operate the Centers in material
compliance with applicable federal, state and local laws, rules and regulations.
SeraCare also agrees to be

                                      -5-
<PAGE>

solely responsible for ensuring that its Centers materially comply with laws,
rules and regulations pertaining to occupational safety and health, blood borne
pathogens and good manufacturing practices.

          4.3   If at any time during the term of this Agreement SeraCare
receives written notice (a "Compliance Notice") from any federal, state or local
governmental entity or agency that any Center is out of compliance in any
material respect with applicable federal, state or local laws, rules or
regulations, SeraCare agrees that it will inform Life Sciences within five (5)
business days of its receipt of such written notification.  For purposes hereof,
a FDA Form 483 notice or similar inspection report shall be deemed to be a
Compliance Notice.  Within thirty (30) days after notifying Life Sciences of
such non-compliance, SeraCare shall deliver written notice informing Life
Sciences of its election either to (i) remove the non-compliant Center from
Exhibit D, or (ii) provide Life Sciences with a written proposal in which
SeraCare sets forth the commercially reasonable efforts that it will use to, and
projected timetable within which it will, bring the non-compliant Center into
material compliance.  If SeraCare elects to try to bring a non-compliant Center
into material compliance and satisfies the concerns of the subject governmental
entity or agency enumerated in the Compliance Notice, or, six months after
responding to such Compliance Notice, SeraCare has received no further
correspondence from the subject governmental entity in respect thereof, the
Center which is the subject of such Compliance Notice shall be deemed to be in
compliance with this Agreement and shall not be removed from Exhibit D.  If
SeraCare elects to try to bring a non-compliant Center in to material compliance
but is unsuccessful, in the reasonable determination of Life Sciences, in
bringing such center into material compliance herewith and with such Compliance
Notice within thirty (30) days of the date of delivery of the written proposal
referred to in clause (ii) of this Section 4.3, either party notify the other
that it elects to remove the non-compliant Center from Exhibit D, and that
Center's removal will be effective immediately upon delivery of that notice.

          4.4   The parties further agree that Life Sciences has the right to
inspect any Center on 24 hours' notice and at Life Sciences' sole expense during
normal business hours to ensure material compliance with applicable regulations.
Life Sciences agrees to conduct such inspection in a reasonable manner.  If
SeraCare receives from Life Sciences a notice of non-compliance resulting from
the inspection, within thirty (30) days of receipt of such notice of such non-
compliance, SeraCare shall deliver written notice informing Life Sciences of its
election either to (i) remove the non-compliant Center from Exhibit D, or (ii)
provide Life Sciences with a written proposal in which SeraCare sets forth the
commercially reasonable efforts that it will use to, and projected timetable
within which it will, bring the non-compliant Center into material compliance.
If SeraCare elects to try to bring a non-compliant Center in to material
compliance, and the relevant remediation efforts cause the Center to be able to
produce Products or collect Referral Donor Products in accordance with the
Minimum Specifications, or Referred Donor Minimum Specifications, as the case
may be, and the Center is otherwise in compliance with all applicable laws and
regulations, the Center which is the subject of the non-compliance shall be
deemed to be in compliance with this Agreement and shall not be removed from
Exhibit D.  If SeraCare elects to try to bring a non-compliant Center into
material compliance but is unsuccessful, in the reasonable determination of Life
Sciences, within thirty (30) days from the date of delivery of the written
proposal referred to in clause (ii) of this Section 4.4, either party notify the
other that it elects to remove the non-compliant Center from Exhibit D, and that
Center's removal will be effective immediately upon delivery of that notice.

                                      -6-
<PAGE>

     5.   Access to Donor Base
          --------------------

          Subject to applicable laws and regulations regarding the
confidentiality of donor information, SeraCare agrees that it shall grant Life
Sciences continuing access during the term of this Agreement to its donor base
of all donors who signed a consent form to allow donor history to be included in
the database, (the "consented donor base") including donor history files.  The
parties acknowledge that as of the date of this Agreement to their knowledge and
after reasonable investigation HIPAA does not apply to SeraCare and the donor
information provided to Life Sciences pursuant to this Agreement.  SeraCare
shall provide Life Sciences such information in a reasonable format requested by
Life Sciences within a reasonable time period, which in no event shall exceed
five (5) business days from the date of the request.

     6.   Warrant
          -------

          Immediately following the Distribution, Life Sciences shall grant
Instituto Grifols, S.A., or its affiliate, a warrant, in accordance with the
terms of the Warrant Agreement attached hereto as Exhibit E, to purchase up to
                                                  ----------
ten (10) percent of the outstanding common stock of Life Sciences immediately
following the Distribution, which, for purposes of example, if calculated as of
the date hereof (assuming conversion of the warrants issued to by SeraCare to
Nap & Co., Fuelship & Co., Northman & Co., and Hare & Co.) would be 1,388,962
shares of common stock of Life Sciences.

     7.   Term and Termination
          --------------------

          7.1   Term.  The term of this Agreement shall commence immediately
                ----
following the Distribution and shall continue until January 24, 2006, unless
earlier terminated or extended as provided herein. This Agreement shall
automatically terminate and be of no further force and effect in the event the
Merger Agreement is terminated.

          7.2   Termination.
                -----------

          (A)   Upon the occurrence of any of the following events, Life
Sciences shall be entitled to (a) receive immediate written notice of the
occurrence of such event and (b) terminate this Agreement immediately by giving
written notice of termination to SeraCare:

                (1)  In the event of insolvency of SeraCare or in the event that
in involuntary or voluntary petition in bankruptcy is filed by, against or on
behalf of SeraCare;

                (2)  In the event SeraCare makes a general assignment for the
benefit of its creditors, or a receiver or trustee is appointed for its business
or property;

                (3)  In the event three (3) or more Centers materially fail any
inspection by Life Sciences, the FDA or any applicable federal, state or local
government agency in any twelve month period, and the circumstances giving rise
to such inspection is not cured as contemplated by Section 4; or

                                      -7-
<PAGE>

                (4)  In the event SeraCare fails to observe the terms of this
Agreement and such failure shall continue to exist for thirty days after written
notice of such failure has been given to SeraCare.

          (B)   Upon the occurrence of any of the following events, SeraCare
shall be entitled to (a) receive immediate written notice of the occurrence of
such event and (b) terminate this Agreement immediately by giving written notice
of termination to Life Sciences:

                (1)  In the event of insolvency of Life Sciences or in the event
that in involuntary or voluntary petition in bankruptcy is filed by, against or
on behalf of Life Sciences;

                (2)  In the event Life Sciences makes a general assignment for
the benefit of its creditors, or a receiver or trustee is appointed for its
business or property; or

                (3)  In the event Life Sciences fails to observe the terms of
this Agreement and such failure shall continue to exist for thirty days after
written notice of such failure has been given to Life Sciences.

          (C)   Failure or delay by either party in terminating this Agreement
following the occurrence of any event specified in Section 8.2 (A) or (B) above
or following any other breach of this Agreement shall not constitute a waiver of
such party's right to terminate this Agreement.

          (D)   Subject to Section 8.14 hereof, no termination of this Agreement
shall release or discharge either of the parties from any debt or liability
which shall have been incurred or accrued prior to the date of termination.

          7.3   Renewal.  The first or any subsequent term of this Agreement
                -------
shall automatically be extended for successive renewal terms of one year each in
duration, on the otherwise same terms and conditions, unless either party
provides written notice of intent not to extend to the other party on or at
anytime before four months prior to the expiration of the then current term.

     8.   Miscellaneous
          -------------

          8.1   Indemnification.  Subject to Section 8.14, each party hereto
                ---------------
(the "Indemnifying Party") shall, to the extent of the Indemnifying Party's
proportionate share of fault, if any, indemnify and hold harmless the other
party and its officers, directors, employees, agents, representatives,
contractors and subcontractors from and against any and all claims or causes of
action brought by any third party or third parties arising out of any act or
omission of the Indemnifying Party in connection with this Agreement.

          8.2   Insurance.  SeraCare agrees to carry at its sole cost and
                ---------
expense during the term of this Agreement and for a reasonable time thereafter,
product and professional liability insurance consistent with prudent business
practices in the industry with respect to the Products and Referred Donor
Services in an amount not less than $300,000 per occurrence for product
liability and not less than $500,000 per occurrence for professional liability.
Life Sciences agrees to carry at its sole cost and expense during the term of
this Agreement and for a

                                      -8-
<PAGE>

reasonable time thereafter, product insurance consistent with prudent business
practices in the industry for the Products or Referred Donor Products in an
amount not less than $300,000 per occurrence for product liability.  If
SeraCare's product liability or professional liability insurance is claims-made
(rather than occurrence) insurance, then, before this Agreement expires,
SeraCare shall purchase tail insurance covering claims that arise after the
Agreement expires.

          8.3  Confidentiality.  The parties agree to maintain the
               ---------------
confidentiality of the contents of this Agreement.  Neither party will
voluntarily disclose the contents of this Agreement unless such disclosure is
pre-approved in writing by the other party, or such disclosure is required by
law or governmental regulation.

          8.4  Entire Agreement.  This Agreement constitutes the entire
               ----------------
agreement between the parties with respect to the subject matter hereof and
shall supersede all prior written and oral and all contemporaneous oral
agreements and understandings with respect to the subject matter hereof.

          8.5  Dispute Resolution.  Resolution of any and all disputes, claims
               ------------------
and causes of action of any nature whatsoever (collectively, "Disputes"),
arising from or relating to this Agreement, shall be exclusively governed by the
provisions of this Section 8.5.

          (a)  Negotiation.  The parties shall make a good faith attempt to
               -----------
resolve any Dispute arising out of or relating to this Agreement through
informal negotiation between appropriate representatives from each of SeraCare
and Life Sciences. If at any time either party feels that such negotiations are
not leading to a resolution of the Dispute, such party may send a notice to the
other party describing the Dispute and requesting a meeting of the senior
executives from each party. Within ten (10) Business Days after such notice is
given, each party shall select appropriate senior executives of each party who
shall have the authority to resolve the matter and shall meet to attempt in good
faith to negotiate a resolution of the Dispute. During the course of
negotiations under this Section 8.5(a), all reasonable requests made by one
party to the other for information, including requests for copies of relevant
documents, will be honored. The specific format for such negotiations will be
left to the discretion of the designated negotiating senior executives but may
include the preparation of agreed upon statements of fact or written statements
of position furnished to the other party. In the event that any Dispute arising
out of or related to this Agreement is not settled by the parties within thirty
(30) days after the first meeting of the negotiating senior executives, either
party may submit the Dispute to arbitration pursuant to Section 8.5(b).

          (b)  Arbitration.  All Disputes not resolved by good faith
               -----------
negotiations among the parties pursuant to Section 8.5(a) within the prescribed
time period shall be submitted to, and determined by, arbitration. Such
arbitration shall proceed in accordance with the then-current rules for
arbitration established by the American Arbitration Association ("AAA"), unless
the parties hereto mutually agree otherwise, and pursuant to the following
procedures:

               (i)  The parties shall attempt in good faith to select from the
     AAA panel one (1) arbitrator mutually acceptable to both parties sitting in
     the state of New York. If the parties fail to agree upon an arbitrator
     within fifteen (15) calendar days, an arbitrator shall be selected by AAA
     in pursuant to the procedures set forth in AAA Rules.

                                      -9-
<PAGE>

     The parties agree that for disputes involving $1 million or more exclusive
     of claimed interest, arbitration fees and costs, the procedures for "large
     complex commercial disputes" of the AAA shall apply. In the event of a
     conflict, the provisions of this Agreement will control.

               (ii)   Reasonable discovery shall be allowed in arbitration.

               (iii)  All proceedings before the arbitrator shall be held in New
     York, New York. The governing law shall be that of California.

               (iv)   The award rendered by the arbitrator shall be final and
     binding, and judgment may be entered in accordance with applicable law and
     in any court having jurisdiction thereof.

               (v)    The award rendered by the arbitrator shall include (A) a
     provision that the prevailing party in such arbitration recover its costs
     relating to the arbitration and reasonable attorneys' fees from the other
     party, (B) the amount of such costs and fees, and (C) an order that the
     losing party pay the fees and expenses of the arbitrator.

               (vi)   The arbitrator shall by the agreement of the parties
     expressly be prohibited from awarding punitive damages in connection with
     any claim being resolved by arbitration hereunder.

               (vii)  All aspects of the arbitration shall be treated as
     confidential. Neither the parties nor the arbitrator may disclose to any
     third party the existence, content or results of the arbitration, except as
     necessary to enforce the award in court or to comply with legal or
     regulatory requirements.

          8.6  Governing Law.  This Agreement shall be construed in accordance
               -------------
with and all Disputes hereunder shall be governed by the laws of the State of
California, excluding its conflict of law rules.

          8.7  Notice. Any notice, demand, offer, request or other communication
               ------
required or permitted to be given by either party pursuant to the terms of this
Agreement shall be in writing and shall be deemed effectively given the earlier
of (i) when received, (ii) when delivered personally, (iii) one (1) business day
after being delivered by facsimile (with receipt of appropriate confirmation),
(iv) one (1) business day after being deposited with an overnight courier
service, or (v) four (4) days after being deposited in the U.S. mail, First
Class with postage prepaid, and addressed to the attention of the party's Chief
Executive Officer at the address of its principal executive office or such other
address as a party may request by notifying the other party thereof in writing.

          8.8  Counterparts.  This Agreement, including other documents referred
               ------------
to herein, may be executed in counterparts, each of which shall be deemed to be
an original but all of which shall constitute one and the same agreement.

          8.9  Binding Effect; Assignment.  This Agreement shall inure to the
               --------------------------
benefit of and be binding upon the parties hereto and their respective legal
representatives and successors,

                                      -10-
<PAGE>

and nothing in this Agreement, express or implied, is intended to confer upon
any other Person any rights or remedies of any nature whatsoever under or by
reason of this Agreement. Except as herein specifically provided to the
contrary, neither party may assign this Agreement or any rights or obligations
hereunder, without the prior written consent of the other party, and any such
assignment shall be void; provided, however, either party (or its permitted
successive assignees or transferees hereunder) may assign or transfer this
Agreement as a whole without consent to an entity that succeeds to all or
substantially all of the business or assets of such party to which this
Agreement relates.

          8.10  Severability.  The parties hereto have negotiated and prepared
                ------------
the terms of this Agreement in good faith with the intent that each and every
one of the terms, covenants and conditions herein be binding upon and inure to
the benefit of the respective parties. Accordingly, if any one or more of the
terms, provisions, promises, covenants or conditions of this Agreement or the
application thereof to any person or circumstance shall be adjudged to any
extent illegal, invalid, unenforceable, void or voidable for any reason
whatsoever by a court of competent jurisdiction, then the parties agree to
negotiate immediately in good faith to amend the Agreement to preserve to the
maximum extent possible its original provisions. If the parties cannot agree on
an amended agreement within 60 days after the court's ruling, this Agreement
shall immediately terminate.

          8.11  Waiver of Breach.  In order to enforce a waiver of any of this
                ----------------
Agreement's provisions, the enforcing party must have an express, written waiver
from the other party. The waiver by either party hereto of a breach or violation
of any provision of this Agreement shall not operate as, or be construed to
constitute, a waiver of any subsequent breach of the same or another provision
hereof.

          8.12  Amendment and Execution.  This Agreement and amendments hereto
                -----------------------
shall be in writing and executed in multiple copies via facsimile or otherwise
on behalf of SeraCare and Life Sciences by their respective duly authorized
officers and representatives. Each multiple copy shall be deemed an original,
but all multiple copies together shall constitute one and the same instrument.

          8.13  Authority.  Each of the parties hereto represents to the other
                ---------
that (a) it has the corporate or other requisite power and authority to execute,
deliver and perform this Agreement, (b) the execution, delivery and performance
of this Agreement by it have been duly authorized by all necessary corporate or
other actions, (c) it has duly and validly executed and delivered this
Agreement, and (d) this Agreement is a legal, valid and binding obligation,
enforceable against it in accordance with its terms subject to applicable
bankruptcy, insolvency, reorganization, moratorium or other similar laws
affecting creditors' rights generally and general equity principles.

          8.14  Limitation of Liability.

          (A)   IN NO EVENT SHALL EITHER PARTY OR ITS SUBSIDIARIES BE LIABLE TO
THE OTHER PARTY OR ITS SUBSIDIARIES FOR ANY SPECIAL, CONSEQUENTIAL, INDIRECT,
INCIDENTAL OR PUNITIVE DAMAGES OR LOST PROFITS, HOWEVER CAUSED AND ON ANY THEORY
OF LIABILITY (INCLUDING

                                      -11-
<PAGE>

NEGLIGENCE) ARISING IN ANY WAY OUT OF THIS AGREEMENT, WHETHER OR NOT SUCH OTHER
PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.

          (B)   IN NO EVENT SHALL SERACARE OR ITS SUBSIDIARIES BE LIABLE TO LIFE
SCIENCES OR ITS SUBSIDIARIES FOR ANY DIRECT, SPECIAL, CONSEQUENTIAL, INDIRECT,
INCIDENTAL OR PUNITIVE DAMAGES OR LOST PROFITS, HOWEVER CAUSED AND ON ANY THEORY
OF LIABILITY (INCLUDING NEGLIGENCE) IN THE EVENT THAT THE PRODUCTS OR REFERRED
DONOR PRODUCTS ARE MANUFACTURED FOR OTHER THAN DIAGNOSTIC PURPOSES, HUMAN
CONSUMPTION OR INJECTION INTO HUMANS.

                                      -12-
<PAGE>

          IN WITNESS WHEREOF, each of the parties has caused this Agreement to
be executed on its behalf by its officers thereunto duly authorized on the day
and year first above written.

SERACARE, INC.                               SERACARE LIFE SCIENCES, INC.

By:    /s/ Barry Plost                       By:    /s/ Jerry L. Burdick
       --------------------------------             ----------------------------
Name:  Barry Plost                           Name:  Jerry L. Burdick
Title: Chief Executive Officer               Title: Executive Vice President

               [SIGNATURE PAGE TO SUPPLY AND SERVICES AGREEMENT]

                                      -13-
<PAGE>

                           LIST OF OMITTED EXHIBITS

The following Exhibits to the Supply and Services Agreement have been omitted
from this Exhibit and shall be furnished to the Commission upon request:

Exhibit                  Document
-------                  --------

D                        Centers

E                        Warrant Agreement

                                      -14-
<PAGE>

                                   EXHIBIT A

                                   Products

<TABLE>
<CAPTION>
          ------------------------------------------------------------
                    Product                            Price
                    -------                            -----
          ------------------------------------------------------------
          <S>                                        <C>
            Reactive Units                           *** per unit
          ------------------------------------------------------------
            Orphan Plasma                            *** per liter
          ------------------------------------------------------------
            Male A/B Plasma                          *** per liter
          ------------------------------------------------------------
            Antibody Positive Plasma                 *** per liter
          ------------------------------------------------------------
            Antibody Negative Plasma                 *** per liter
          ------------------------------------------------------------
</TABLE>

<TABLE>
<CAPTION>
          ------------------------------------------------------------
            Referred Donor Services                    Price
            -----------------------                    -----
          ------------------------------------------------------------
          <S>                                        <C>
            Referred Donor Plasma                    *** per donor
          ------------------------------------------------------------
            Referred Donor Blood                     *** per donor
          ------------------------------------------------------------
</TABLE>

______________________
*** Confidential information omitted and filed separately with the Securities
and Exchange Commission.

                                      -15-
<PAGE>

                                   EXHIBIT B

                                     ***

______________________
*** Confidential information omitted and filed separately with the Securities
and Exchange Commission.

                                      -16-
<PAGE>

                                   EXHIBIT C

                                     ***

_____________________
*** Confidential information omitted and filed separately with the Securities
and Exchange Commission.

                                      -17-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00027-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00027-of-00352.parquet"}]]